Posted by AGORACOM-JC
at 4:03 PM on Tuesday, August 24th, 2021
Kidoz owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss their stunning Q2 growth, and more.
Q2 2021 highlights include:
Total Revenue of $2,177,505 – growth of 196% compared to Q2 2020 Total Revenue of $736,827.
AdTech revenue of $2,120,500 – growth of 247% compared to Q2 2020 AdTech Revenue $611,709.
Gross Profit of $1,024,333 – growth of 214% compared to Q2 2020 Gross Profit of $325,769.
EBITDA of $48,079 a 124% improvement from an EBITDA loss of ($197,057) in Q2 2020.
Sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison talk about the relationship between psychedelics and psychosis and discuss the abuse potential of ketamine.
Amirah Al Idrus explores the regulatory issues facing psychedelics, the setting in which they’re administered and how traditional business models may need to evolve in the process. At Novamind, we’re building the infrastructure to expand access to psychedelics in anticipation of their FDA approval. We’ve developed and are developing psychedelic therapy protocols to target difficult-to-treat mental health conditions that are underserved by the current standard of care. You can learn more about those treatment protocols here.
We know ketamine’s power to treat depression. “Within hours, a single dose of the psychedelic substance has been shown to curb suicidal intent, and recent clinical trials suggest these effects work on two thirds of patients, lasting for up to several weeks before fading away.” But recent results are getting us closer to the scientific reason why—ketamine may be responsible for decreasing the release of glutamate in our brains.
Posted by AGORACOM-JC
at 4:01 PM on Wednesday, August 18th, 2021
Liquid Avatar Technologies (LQID: CSE) (LQAVF: OTCQB) is a global blockchain, personal identity & Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform (www.liquidavatar.com)
GENERALLY – Liquid Avatar Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
SPECIFICALLY – Liquid Avatar Specializes In
Continuous Online Identity Verification
Personal Identity Management
Personal Data Monetization.
The LAVCE (Liquid Avatar Credentials Ecosystem) currently supports verifiable credentials by creating a Trust Triangle between the Issuer of a credential, such as a government, health provider, workplace or school, the credential Holder (the data subject), and the Verifier (receiver of data) that is working to validate each unique data transaction. Far more secure and reliable than paper-based credentials, contract tracing forms, and traditional apps, the LAVCE and verifiable credentials can effectively reduce or eliminate fraud as all functions are supported by cryptographic blockchain solutions using the Indicio Network , the premier enterprise blockchain network for identity.
David Lucatch, CEO says it best, “Quick and easy verification for vaccine status with robust protection against fraudulent issuance is just one of many of the LAVCE’s important applications, Our communities just started opening up and it’d be a potential economic disaster if we had to collectively shut down again. We believe that it’s not enough to just say that you’re vaccinated or tested, we need a seamless, non-invasive, and privacy-respecting method for organizations to verify that individuals are immunized so that they can safely access their services…”
Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 4:04 PM on Monday, August 16th, 2021
In an interview just over a month ago, Empower Clinics CEO Steve McAuley talked about how the Company is in full-blown growth mode that were best summarized as follows:
“Multiple opportunities have been percolating and I’m going to turn up the heat”
To this added seeing
“substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.
Today McAuley and the team at Empower backed up those words with this announcement:
“The Company can now confirm the first new clinic launches will take place in September – location and ribbon cutting ceremonies to be announced – with rollouts of further locations continuing on a regular basis from that point forward.”
In today’s interview McAuley takes shareholders through a detailed overview of the foundation that has now been built, ready to launch and strong enough to catapult Empower into a completely new orbit. Watch this great interview. Welcome to the launch pad.
Posted by AGORACOM
at 12:15 PM on Monday, August 16th, 2021
Biotech companies, by their very nature, can often be difficult to understand for investors… but in order to understand Cardiol, all you have to know is that the firm is developing therapies for heart disease and heart failure through cannabidiols.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).
The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™.
CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free. (less than 10 ppm)
Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.
This week, the company passed another major milestone, moving from the OTC Markets to a U.S. listing on NASDAQ, under the symbol $CRDL – the same as its TSX symbol.
And with the COVID-19 Delta Variant running rampant through North America, Cardiol’s work has become more important than ever.
We sat down with David Elsley, Cardiol Therapeutics’ President & CEO, to discuss the uplisting…
Posted by AGORACOM-JC
at 10:56 AM on Monday, August 16th, 2021
When it comes to small-cap companies, tech-focused Datametrex AI (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.
In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s explosive H1-2021.
Financial Highlights include:
Revenue of $29,494,191 compared to revenue of $2,763,796 (same period 2020)
Net earnings of $10,410,485 compared to ($1,590,239).
EBITDA of $12,250,211 compared to ($1,197,679).
Cash balance significantly increased to $10,555,375 from $1,971,987 end of 2020.
In this episode, Dr. Steve Thayer, Dr. Reid Robison, and Vhari Macbeth discuss the concept of the self, multiple “selves”, and how we work with “selfhood” in psychedelic therapy.
Novamind has completed the sale of its investment in the Synthesis Institute, a strategic decision that enables Novamind to focus on the expansion of its network of clinics and clinical research sites located in the U.S.
“Novamind has experienced rapid growth in its two core businesses,” said Yaron Conforti, Chief Executive Officer and Director. “We’ve established a unique and scalable business model that serves clients at our clinics and drug developers at our research sites. We are now exclusively focused on the continued growth of our clinic and contract research organization businesses, with near-term expansion into other U.S. states and an exciting pipeline of clinical trials.”
New research indicates that ketamine, in combination with light, may be able to temporarily restore our brains back to the plasticity seen in critical growth periods. More research is needed, but initial studies are promising. “Whether or not ketamine and/or flickering light could enable temporary neural plasticity in other parts of the brain, perhaps to treat language disorders or learning disabilities, is also “an intriguing possibility and would need further experiments,” Siegert added.” We look forward to further research exploring the life changing potential of ketamine.
Zoe Cormier explores the benefits and costs of psychedelic therapy models—group vs solo. Strong anecdotal evidence is provided for the group therapy model. In practice, a case can be made for both, which is why the treatment protocols available at our Cedar Psychiatry clinics include group and solo participation. You can learn more about them here.
Posted by AGORACOM-JC
at 9:11 AM on Wednesday, August 11th, 2021
Liquid Avatar Technologies (LQID: CSE) (LQAVF: OTCQB) is a global blockchain, personal identity & Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform (www.liquidavatar.com)
GENERALLY – Liquid Avatar Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
SPECIFICALLY – Liquid Avatar Specializes In
Continuous Online Identity Verification
Personal Identity Management
Personal Data Monetization.
Liquid Avatar Credentials Ecosystem (LAVCE) enables people to share the results of a COVID test in a way that preserves their privacy and prevents fraud. The LAVCE platform can be integrated with healthcare facilities, testing labs, government agencies, schools, sports arenas, transportation, trade shows, and workplaces to confirm health status and assist efforts to reduce new outbreaks.
David Lucatch, CEO says it best, “It’s a privacy and security gamechanger, because there’s no need for a third party to access private health data to prove a test result is valid and from a trusted source. That’s huge. That solves the compliance problem.”
Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 4:19 PM on Monday, August 9th, 2021
Most of us know drones for their recreational uses or perhaps even as simple commercial applications for things like real estate videos.
But the fact of the matter is that drone usage is about to go parabolic with huge corporations adopting them for a wide-use of applications that most never dreamed of such as:
To provide Internet connections in remote locations.
To collect crowd data.
In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones themselves (hardware) to drone technology and solutions (software)… and the one company that is delivering the most challenging applications is Draganfly Inc. (DPRO: NASDAQ) (DPRO: CSE)
DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:
Established in 1998 DFLY is considered the oldest commercial drone company in the world
Built the first drone that saved a life
Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
Detect infectious conditions in a person from a distance of 190 feet
Conduct phenotyping, data collection and analysis by the USDA
With all of this under the Company’s belt, it’s easy to see why the company recently uplisted to the NASDAQ.
If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or want to learn, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.
Where other treatments for depression have failed, ketamine has changed lives. Chief Medical Officer Dr. Reid Robison spoke to Leafly about how ketamine is changing mental healthcare.
“Ketamine is now emerging as a powerful catalyst to accelerate the healing and recovery process in individuals suffering from a wide array of mental health symptoms.”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer, Vhari MacBeth, and Derick Moody explore the curious phenomenon of self-sabotage.
We are pleased to announce the appointment of Samantha DeLenardo as Vice President, Communications to lead Novamind’s communications, marketing and investor relations.
“At Novamind, we care deeply about the clients and families we serve,” said DeLenardo. “We are prepared to meet this transformative moment for psychedelics and mental health, thanks in large part to the courage and years of advocacy by people with lived expertise and medical practitioners. Novamind understands both the responsibility and opportunity before us, and I look forward to sharing the Company’s story with the world.”
In a big step forward for psychedelics, Usona Institute announced the groundbreaking of a Global Center in Psychedelic Science. The campus will “support a blend of disciplines in psychedelic science and education.” It’s another example of momentum building around the truly extraordinary therapeutic potential of psychedelics.
Words have not been minced. CEO Spencer Hawkswell comments on the current exemptions for the terminally ill in Canada, “We are going to be lobbying hard to get those regulations set into law to make sure that Canadians can realize their rights to psilocybin.” We look forward to that access expanding to all Canadians.
